500 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Bought by Atlas Capital Advisors Inc.

Atlas Capital Advisors Inc. purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 500 shares of the company’s stock, valued at approximately $31,000.

A number of other hedge funds have also modified their holdings of TMDX. Hager Investment Management Services LLC acquired a new stake in shares of TransMedics Group during the fourth quarter worth about $33,000. Sachetta LLC purchased a new position in TransMedics Group during the 4th quarter worth approximately $40,000. AlphaQuest LLC acquired a new stake in TransMedics Group during the 4th quarter valued at approximately $52,000. Quarry LP boosted its holdings in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares during the last quarter. Finally, National Bank of Canada FI increased its stake in shares of TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after acquiring an additional 262 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TMDX has been the subject of a number of research reports. Piper Sandler decreased their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Canaccord Genuity Group restated a “buy” rating and issued a $104.00 target price on shares of TransMedics Group in a research note on Tuesday, March 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Robert W. Baird lowered their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $67.67 on Friday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market capitalization of $2.28 billion, a PE ratio of 71.99 and a beta of 2.14. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a fifty day moving average of $70.07 and a two-hundred day moving average of $85.25.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.